IMMUNOHISTOCHEMISTRY, CD 30

The Immunohistochemistry (IHC) – CD30 test is a specialized diagnostic test used to detect CD30 protein expression in tissue samples. CD30 is a cell membrane protein that belongs to the tumor necrosis factor receptor family and is commonly expressed on activated lymphocytes and certain malignant cells.

This test is widely used in hematopathology for diagnosing and classifying lymphomas, particularly Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). Detecting CD30 helps pathologists identify abnormal lymphoid cells and confirm specific lymphoma subtypes with greater accuracy.

The CD30 marker is especially useful in diagnosing:

• Classical Hodgkin lymphoma
• Anaplastic large cell lymphoma (ALCL)
• Certain activated B-cell and T-cell lymphomas
• Lymphoproliferative disorders
• Selected reactive lymphoid lesions

CD30 expression is important not only for diagnosis but also for treatment planning, as some targeted therapies are specifically designed for CD30-positive cancers.

The CD30 IHC test is often performed alongside markers such as CD15, CD3, CD20, ALK, PAX5, and Ki-67 for complete lymphoma characterization and precise classification.

Benefits of the Test

The CD30 test offers several important clinical benefits:

• Detects CD30 protein expression accurately
• Helps diagnose Hodgkin lymphoma and ALCL
• Supports lymphoma classification
• Identifies eligibility for targeted therapies
• Improves diagnostic precision
• Helps guide treatment planning

This test is essential for accurate lymphoma diagnosis.

Why Doctors Recommend This Test

Doctors recommend the CD30 test when lymphoma or lymphoid tissue abnormalities are suspected.

It is commonly advised for:

• Suspected Hodgkin lymphoma diagnosis
• Evaluation of anaplastic large cell lymphoma
• Lymph node biopsy classification
• Assessment of activated lymphoid lesions
• Advanced hematopathology confirmation cases

The results help hematologists and oncologists determine the correct diagnosis and treatment strategy.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected lymph node biopsy or tissue specimens.

Normal Reporting Time

The usual turnaround time for the CD30 IHC test is 2 to 5 working days, depending on tissue complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with enlarged lymph nodes
• Individuals suspected of lymphoma
• Patients requiring lymphoma subtype classification
• Cases needing targeted therapy evaluation
• Oncology patients requiring accurate pathology diagnosis

The IHC CD30 test is an essential diagnostic tool in hematopathology. It supports precise lymphoma diagnosis, identifies treatment options, and helps improve patient outcomes through personalized care.